2021
DOI: 10.3390/cancers13030462
|View full text |Cite
|
Sign up to set email alerts
|

The Relevance of the SH2 Domain for c-Src Functionality in Triple-Negative Breast Cancer Cells

Abstract: The role of Src family kinases (SFKs) in human tumors has been always associated with tyrosine kinase activity and much less attention has been given to the SH2 and SH3 adapter domains. Here, we studied the role of the c-Src-SH2 domain in triple-negative breast cancer (TNBC). To this end, SUM159PT and MDA-MB-231 human cell lines were employed as model systems. These cells conditionally expressed, under tetracycline control (Tet-On system), a c-Src variant with point-inactivating mutation of the SH2 adapter dom… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 63 publications
0
5
0
Order By: Relevance
“…12 In TNBC, c-Src's SH2 domain has been shown to be important for tumorigenicity. 14 PROTACs provide a means of chemical knockdown 15 that will prevent both catalytic and noncatalytic functions, and we were thus interested in developing a PROTAC for c-Src.…”
Section: ■ Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…12 In TNBC, c-Src's SH2 domain has been shown to be important for tumorigenicity. 14 PROTACs provide a means of chemical knockdown 15 that will prevent both catalytic and noncatalytic functions, and we were thus interested in developing a PROTAC for c-Src.…”
Section: ■ Introductionmentioning
confidence: 99%
“…Upon knockdown (e.g., with siRNA), triple-negative breast cancer (TNBC) and basal bladder cancers exhibit decreased proliferation and invasion properties. , Unfortunately, studies with small-molecule inhibitors of c-Src (including: dasatinib, bosutinib, and ponatinib) failed to recapitulate the strong anticancer phenotype observed from genetic knockdown of c-Src and were not successful in the clinic. , Many noncatalytic functions have been reported for c-Src, typically involving protein–protein interaction between a partner protein and c-Src’s SH2 and SH3 domains. , Several binding partners of c-Src have been identified, including epidermal growth factor receptors, focal adhesion kinase, and hormone receptors . In TNBC, c-Src’s SH2 domain has been shown to be important for tumorigenicity . PROTACs provide a means of chemical knockdown that will prevent both catalytic and noncatalytic functions, and we were thus interested in developing a PROTAC for c-Src.…”
Section: Introductionmentioning
confidence: 99%
“…[16,18,39] YXXM interacts with signal transduction proteins containing the SH2 domain, [11,16] which is crucial for the stemness of CSCs. [40,41] Based on this information, we asked whether the CD96 YXXM motif is responsible for BCSCs regulation. We first examined the expression and phosphorylation of a series of SH2-containing proteins known to participate in CSCs regulation.…”
Section: Cd96 Regulates Mitochondrial Fao Via the Src-stat3 Pathway I...mentioning
confidence: 99%
“…The Src family kinases (SFKs) are a family of non-receptor tyrosine kinases responsible for signal transduction during many cellular events, such as differentiation, adhesion, and migration. This family is composed of nine members, whose distinguish feature is a modular structure containing the Src homology domains 2 and 3 (SH2 and SH3), which are involved in protein-protein interactions ( Espada and Martin-Perez, 2017 ; Shah et al, 2018 ; Mayoral-Varo et al, 2021 ). Altered Src activity is associated with enhanced tumor progression, and several mechanisms have been proposed to explain it.…”
Section: Golgi Signaling Molecules and Cancermentioning
confidence: 99%